I dunno why people rather to believe on this kind of non kkm license and non experience company supply vaccine to whole malaysia instead of both big grand exciting pharma announced by gov earlier...
duopharma and pharmaniaga are not attractive because they are overpriced. and they have not mentioned which corona virus vaccine they are getting. all speculation about them. and the yield is very little. no point buying that stocks
duopharma is now a penny stock. overpriced with very low yields, low profits to show. it has proven over the last 2 months unable to breach more than 3.50. it will stay at this range. dead...no point buying. buy the cheaper ones can make more money % yield is higher as you can see market is smart. volume is high for stocks like solution. solid and steady...on a strong upward trend. 1 ringgit is the market target.
Pay attention to this declaration: "The success of commercialising the vaccine is subject to completion of the phase 3 trial and obtaining the regulatory approvals."
We refer to your Company’s announcement dated 19 August 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:-
1) The total capital and investment outlay required to be committed by SGB in connection with the MOU / proposed new business of the fill and finish of bulk COVID-19 vaccine supplied by CanSinoBIO and the marketing and distribution of the said vaccine in Malaysia (“New Business”), the source(s) of funding and the breakdown thereof. 2) The relevant regulatory approvals, permits and/or licenses required to be obtained in order for SGB to perform its responsibilities under the New Business. To also state whether the Company has secured any of these regulatory approvals, permits and/or licences, and the relevant dates of application and approval. 3) The business risks in connection with the MOU / New Business. 4) The stage of development and production of COVID-19 vaccine by CanSinoBIO. 5) The Company’s future plans and prospects in connection with the collaboration / New Business.
Please furnish Bursa Securities with your reply within one (1) market day from the date hereof.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
KenKen84
285 posts
Posted by KenKen84 > 2020-08-24 13:13 | Report Abuse
I dunno why people rather to believe on this kind of non kkm license and non experience company supply vaccine to whole malaysia instead of both big grand exciting pharma announced by gov earlier...